

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

RAMON SALAZAR,^a ROCIO GARCIA-CARBONERO,^b STEVEN K. LIBUTTI,^c ANDREW E. HENDIFAR,^d ANA CUSTODIO,^e ROSINE GUIMBAUD,^f CATHERINE LOMBARD-BOHAS,^g SERGIO RICCI,^h HEINZ-JOSEF KLÜMPEN,ⁱ JAUME CAPDEVILA,^j NICHOLAS REED,^k ANNEMIEK WALENKAMP,^l ENRIQUE GRANDE,^m SUFIYA SAFINA,ⁿ TIM MEYER,^o OLIVER KONG,^p HERVE SALOMON,^q RANJANA TAVORATH,^p JAMES C. YAO^r

^aDepartment of Medical Oncology, Institut Català d'Oncologia-IDIBELL-CIBERONC, Universitat de Barcelona, Barcelona, Spain;

^bDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; ^cAlbert Einstein College of Medicine, New York City, New York, USA; ^dDavid Geffen School of Medicine and Cedars Sinai Medical Center, Los Angeles, California, USA;

^eDepartment of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain; ^fDepartment of Digestive Medical Oncology (IUCT-RL), Centre Hospitalier Universitaire de Toulouse, Toulouse, France; ^gCentre Hospitalier Lyon Sud, Pierre-Bénite, France; ^hDivision of Medical Oncology, S Chiara University Hospital,

Pisa, Italy; ⁱDepartment of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands; ^jVall Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ^kBeatson West of Scotland Cancer Centre, Glasgow, Scotland; ^lUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ^mDepartment of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain; ⁿDepartment of Biochemistry, Kazan State Medical University, Kazan, Russia; ^oRoyal Free Hospital, London, United

Kingdom; ^pNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; ^qNovartis Pharma S.A.S., Rueil-Malmaison, France;

^rThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence: Ramon Salazar, M.D., Ph.D., Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, Universitat de Barcelona, Barcelona, Spain 08908. Telephone: 34-93-2607744; e-mail: ramonsalazarsole@iconcologia.net Received August 8, 2017; accepted for publication October 30, 2017; published Online First on December 14, 2017. © AlphaMed Press; the data published online to support this summary is the property of the authors. <http://dx.doi.org/10.1634/theoncologist.2017-0144>

TRIAL INFORMATION

- ClinicalTrials.gov Identifier: NCT01628913
- Sponsor(s): Novartis Pharmaceuticals Corporation
- Principal Investigator: James C. Yao
- IRB Approved: Yes

LESSONS LEARNED


- Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile.
- The hypothesis of dual targeting of the phosphatidylinositol 3-kinase and mammalian target of rapamycin pathways in patients with advanced pancreatic neuroendocrine tumors may warrant further study using other agents.

ABSTRACT

Background. This phase II study investigated whether targeting the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway via PI3K, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) inhibition using BEZ235 may be more effective than mTORC1 inhibition with everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) who are naïve to mTOR inhibitor therapy. **Methods.** Patients with advanced pNET were randomized (1:1) to oral BEZ235 400 mg twice daily or oral everolimus 10 mg once daily on a continuous dosing schedule. The primary endpoint was progression-free survival (PFS). Secondary endpoints included safety, overall response rate (ORR), overall survival (OS), and time to treatment failure.

Results. Enrollment in this study was terminated early (62 enrolled of the 140 planned). The median PFS was 8.2 months (95% confidence interval [CI]: 5.3 to not evaluable [NE]) with BEZ235 versus 10.8 months (95% CI: 8.1–NE) with everolimus (hazard ratio 1.53; 95% CI: 0.72–3.25). The most commonly reported all-grade adverse events (>50% of patients regardless of study treatment relationship) with BEZ235 were diarrhea (90.3%), stomatitis (74.2%), and nausea (54.8%).

Conclusion. BEZ235 treatment in mTOR inhibitor-naïve patients with advanced pNET did not demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. *The Oncologist* 2018;23:766–e90



Number of patients at risk		0	2	4	6	8	10	12	14	16	18
BEZ235	31	24	17	15	12	6	2	1	1	0	0
Everolimus	31	30	26	20	19	13	7	3	1	0	0

Figure 1. Kaplan-Meier plot of progression-free survival per local radiologic review. Abbreviations: CI, confidence interval; NE, not evaluable; PFS, progression-free survival.

DISCUSSION

This phase II study aimed to investigate whether targeting the PI3K/mTOR pathway via PI3K, mTORC1, and mTORC2 adenosine triphosphate (ATP) site inhibition using BEZ235 is more effective than mTORC1 allosteric inhibition with everolimus in patients with advanced pNET who are naïve to mTOR inhibition therapy. However, emerging data suggesting an unfavorable safety profile and unpredictable bioavailability led to the sponsor's decision to halt the development of BEZ235 in all oncology indications including pNET, and enrollment in this study was terminated before the planned 70 patients had been randomized in each treatment arm and before a preplanned primary analysis after 70 disease progression events was reached.

The results of the study suggest that the efficacy of BEZ235 did not surpass that of everolimus in this setting (Fig. 1). The median PFS of 10.8 months observed with everolimus in this study is comparable to prior data in this setting (RADIANT-3 trial; [1]). The median PFS of 8.2 months observed with BEZ235 exceeded that of 4.6 months in the placebo arm of RADIANT-3, indicating some degree of efficacy [1]. ORR (9.7%) was similar in both groups, suggesting that a small degree of tumor shrinkage was observed with both treatments. Disease control rate was substantially lower with BEZ235 (61.3%) than with everolimus (90.3%), although the high rate of unknown tumor responses among patients in the BEZ235-treated group (25.8%) versus the everolimus-treated group (6.5%) precludes any meaningful

comparison of disease stabilization between the groups. A small numerical difference in the estimated 6-month OS rate was observed with BEZ235 (96.6%) versus everolimus (90.3%), which should be interpreted with caution due to the early termination of the study, limited number of patients, and very few on-study deaths during the trial.

All adverse events (AEs) observed with BEZ235 and everolimus during the study were consistent with their known safety profiles and no unexpected events were reported [1–4]. However, this study indicated that BEZ235 was potentially less well tolerated than everolimus. More grade 3/4 AEs were reported with BEZ235 (83.9%) versus everolimus (71.0%) and discontinuations due to AEs were twice as frequent with BEZ235 versus everolimus (38.7 vs. 16.1%, respectively). The poor tolerability of BEZ235 versus everolimus may explain why patients randomized to this treatment were exposed to study medication for almost half the duration of time as those randomized to everolimus (22.9 vs. 39.4 weeks, respectively). This short duration of treatment time may have negatively impacted BEZ235 efficacy outcomes.

mTOR inhibitor-naïve patients with advanced pNET on treatment with BEZ235 did not demonstrate superior efficacy compared with everolimus and may have a poorer tolerability profile. However, the hypothesis of dual targeting of the PI3K and mTOR pathways in patients with advanced pNET may still warrant further study using other agents with more favorable safety profiles.

TRIAL INFORMATION

Disease	Neuroendocrine
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	2 prior regimens
Type of Study – 1	Phase II
Type of Study – 2	Randomized
Primary Endpoint	Progression-free survival
Secondary Endpoint	Safety
Secondary Endpoint	Overall response rate
Secondary Endpoint	Overall survival
Secondary Endpoint	Time to treatment failure

Additional Details of Endpoints or Study Design

The main analysis was originally intended to be performed after 70 patients had experienced progression of the disease or death due to any cause. Based on this, an indication for a longer PFS under BEZ235 would be achieved when the following two efficacy criteria are both met: (a) the estimated hazard ratio (HR) is ≤ 0.75 and (b) the posterior probability that the HR is < 1 is at least 90%: $P(\text{post}(\text{HR} < 1) \geq 0.9)$. But due to early enrollment study termination on October 29, 2013, the 62 patients randomized were analyzed mainly for descriptive purpose after 6 months after the last patient started study treatment.

Investigator's Analysis	Poorly tolerated/not feasible
-------------------------	-------------------------------

DRUG INFORMATION FOR PHASE II EVEROLIMUS

Drug 1	
Generic/Working Name	Everolimus
Trade Name	Afinitor
Company Name	Novartis Pharmaceuticals Corporation
Drug Type	Targeted therapy
Drug Class	m-TOR
Dose	10 mg per flat dose
Route	p.o.
Schedule of Administration	Once daily, every day (28-day cycles)

DRUG INFORMATION FOR PHASE II BEZ235

Drug 1	
Generic/Working Name	BEZ235
Trade Name	Dactolisib
Company Name	Novartis Pharmaceuticals Corporation
Drug Type	Small molecule
Drug Class	PI3 kinase
Dose	400 mg per flat dose
Route	p.o.
Schedule of Administration	Twice daily, every day (28-day cycles)

PATIENT CHARACTERISTICS FOR PHASE II EVEROLIMUS

Number of Patients, Male	15
Number of Patients, Female	16
Age	Median: 57
Performance Status: ECOG	0 – 20 1 – 11 2 – 0 3 – Unknown –

PATIENT CHARACTERISTICS FOR PHASE II BEZ235

Number of Patients, Male	17
Number of Patients, Female	14
Age	Median: 56 years
Performance Status: ECOG	0 — 20 1 — 10 2 — 1 3 — Unknown —

PRIMARY ASSESSMENT METHOD FOR PHASE II EVEROLIMUS

Title	Total patient population
Number of Patients Screened	31
Number of Patients Enrolled	31
Number of Patients Evaluable for Toxicity	31
Number of Patients Evaluated for Efficacy	31
Evaluation Method	Response Evaluation Criteria in Solid Tumors (RECIST) 1.0
Response Assessment CR	<i>n</i> 5 0 (0%)
Response Assessment PR	<i>n</i> 5 3 (9.7%)
Response Assessment SD	<i>n</i> 5 25 (80.6%)
Response Assessment PD	<i>n</i> 5 1 (3.2%)
Response Assessment OTHER	<i>n</i> 5 2 (6.5%)
(Median) Duration Assessments PFS	10.8 months
(Median) Duration Assessments Duration of Treatment	39.4 weeks

PRIMARY ASSESSMENT METHOD FOR PHASE II BEZ235

Title	Total patient population
Number of Patients Screened	31
Number of Patients Enrolled	31
Number of Patients Evaluable for Toxicity	31
Number of Patients Evaluated for Efficacy	31
Evaluation Method	RECIST 1.0
Response Assessment CR	<i>n</i> 5 0 (0%)
Response Assessment PR	<i>n</i> 5 3 (9.7%)
Response Assessment SD	<i>n</i> 5 16 (51.6%)
Response Assessment PD	<i>n</i> 5 4 (12.9%)
Response Assessment OTHER	<i>n</i> 5 8 (25.8%)
(Median) Duration Assessments PFS	8.2 months
(Median) Duration Assessments Duration of Treatment	22.9 weeks

TREATMENT-EMERGENT ADVERSE EVENTS (>15%)				
Adverse event	BEZ235 (n 531), n (%)		Everolimus (n 531), n (%)	
	All grades	Grade 3/4	All grades	Grade 3/4
Any event	31 (100)	26 (83.9)	30 (96.8)	22 (71.0)
Diarrhea	28 (90.3)	5 (16.1)	17 (54.8)	1 (3.2)
Stomatitis	23 (74.2)	4 (12.9)	20 (64.5)	2 (6.5)
Nausea	17 (54.8)	2 (6.5)	10 (32.3)	0
Vomiting	15 (48.4)	2 (6.5)	7 (22.6)	1 (3.2)
Asthenia	13 (41.9)	5 (16.1)	13 (41.9)	1 (3.2)
Abdominal pain	12 (38.7)	3 (9.7)	8 (25.8)	0
Rash	11 (35.5)	0	13 (41.9)	0
Hyperglycemia	10 (32.3)	5 (16.1)	11 (35.5)	2 (6.5)
Appetite decreased	9 (29.0)	2 (6.5)	13 (41.9)	1 (3.2)
Pyrexia	9 (29.0)	1 (3.2)	4 (12.9)	0
Anemia	8 (25.8)	2 (6.5)	11 (35.5)	3 (9.7)
Fatigue	7 (22.6)	3 (9.7)	10 (32.3)	2 (2.5)
Blood creatinine increased	6 (19.4)	0	2 (6.5)	0
Headache	6 (19.4)	0	7 (22.6)	0
Edema peripheral	6 (19.4)	0	11 (35.5)	4 (12.9)
Pruritus	6 (19.4)	0	2 (6.5)	0
Abdominal pain upper	5 (16.1)	1 (3.2)	5 (16.1)	0
ALT increased	5 (16.1)	3 (9.7)	3 (9.7)	1 (3.2)
Dysgeusia	5 (16.1)	0	3 (9.7)	0
Constipation	4 (12.9)	0	5 (16.1)	0
Epistaxis	4 (12.9)	0	5 (16.1)	0
Weight decreased	4 (12.9)	0	6 (19.4)	1 (3.2)
Cough	3 (9.7)	0	8 (25.8)	0
Dyspnea	2 (6.5)	1 (3.2)	5 (16.1)	1 (3.2)
Nasopharyngitis	2 (6.5)	0	5 (16.1)	0
Dry skin	0	0	8 (25.8)	0
Hypertriglyceridemia	0	0	5 (16.1)	2 (6.5)
Platelet count decreased	0	0	7 (22.6)	0
Pneumonitis	0	0	5 (16.1)	1 (3.2)

Abbreviation: ALT, alanine aminotransferase.

Completion
 Terminated Reason
 Investigator's Assessment

Study terminated before completion
 Toxicity
 Poorly tolerated/not feasible

Two targeted agents have been approved for the treatment of locally advanced and metastatic pancreatic neuroendocrine tumors (pNET) based on improvements in progression-free survival versus placebo: everolimus, a mammalian target of rapamycin (mTOR) inhibitor, and sunitinib, a multitargeted tyrosine kinase inhibitor. Everolimus therapy has demonstrated considerable clinical benefit in the treatment of advanced pNET. However, de novo and acquired resistance to therapy have been observed. Such resistance may stem from enhanced activation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway [5–7]. Everolimus specifically inhibits the mTOR complex 1 (mTORC1) but does not block mTOR complex 2 (mTORC2)-mediated activation of AKT. It is postulated that activation of AKT by way of insulin-like growth factor 1/insulin-like growth factor 1 receptor and mTORC2 signaling activation due to the inhibition of S6 kinase (S6K) negative feedback are mechanisms of everolimus treatment resistance [1, 8]. Samples from patients with advanced solid tumors and neuroendocrine tumors have shown that treatment with everolimus led to increases in activated AKT through the silencing of an S6K-dependent negative feedback-induced loop, especially in patients with clinical responses [9, 10]. Therefore, it is possible that targeting the PI3K/mTOR pathway via PI3K, mTORC1, and mTORC2 inhibition may circumvent treatment resistance and improve outcomes for patients with pNET compared with inhibition of mTORC1 alone.

These observations provided impetus for the development of dual PI3K/mTOR inhibitors such as dactolisib (BEZ235), SAR245409 (XL765), BGT226, and apitolisib (GDC-0980), which have subsequently been evaluated in a variety of solid tumors

[2, 12–15]. BEZ235 is a novel pan-class IPI3K inhibitor that also inhibits mTORC1 and mTORC2 [16]. BEZ235 inhibits kinase activity by binding to the ATP-binding cleft of these enzymes, which occurs through a different mechanism to allosteric inhibition by everolimus, thus avoiding potential rapamycin complex binding site mutations [17].

In preclinical studies, BEZ235 was shown to have potent antitumor activity resulting in G1 phase cell cycle arrest in vivo that was synergistic with the activity of other anti-cancer drugs, including everolimus [18, 19]. Furthermore, BEZ235 overcame long-term acquired everolimus resistance in human pNET cell lines, leading to further clinical evaluation of this compound in clinical trials [20]. In the clinical setting, a phase I study involving patients with advanced solid tumors treated with BEZ235 as a single agent demonstrated both clinical activity (45% had stable disease) and acceptable tolerability [2].

The safety and tolerability profile of BEZ235 observed in this study was consistent with the known experience, with no new signal identified. However, treatment with BEZ235 single agent 400 mg bid was accompanied with toxicity requiring frequent treatment modifications and discontinuations in this population with advanced pNET. Adverse events that were frequently reported in phase I studies with the other dual PI3K/mTOR inhibitors in development (XL765, GDC-0980, GSK2126458, and PF-04691502) were similar to those seen in this phase I trial of BEZ235, including nausea, vomiting, diarrhea, anorexia, and skin disorders [2]. Taken together, dual inhibition of PI3K-mTOR was associated with higher incidences of toxicity [21]. The shorter duration of treatment of BEZ235 (22.9 weeks) compared with everolimus (39.4 weeks) because of poor tolerability may have negatively impacted BEZ235 efficacy outcomes. Efficacy may also have been restricted by the high intra- and interpatient pharmacokinetic variability with BEZ235 administration observed in previous clinical studies [2, 4, 22, 23], and bioavailability issues [24]. In conclusion, the results of this study suggest that the modest efficacy and poor tolerability of pan-PI3K inhibitors and dual PI3K/mTOR inhibitors may limit further clinical development of these compounds.

ACKNOWLEDGMENTS

We thank the patients enrolled in this study and their families, in addition to Nabanita Mukherjee for support with statistical analyses. Medical editorial assistance was provided by Sai Krishna Arepalli, Ph.D. (Novartis Pharmaceuticals Corporation).

DISCLOSURES

Ramon Salazar: Novartis (C/A, H); Rocio Garcia-Carbonero: Ipsen, Novartis, AAA Pharmaceutical Inc., Pfizer (C/A), Ipsen, Novartis, Pfizer (RF); Andrew E. Hendifar: Ipsen, Novartis, Abbvie (C/A); Catherine Lombard-Bohas: Ipsen, Novartis, Pfizer (C/A, SAB); Heinz-Josef Klümper: Ipsen (C/A), Bayer, Novartis (RF); Jaume Capdevila: Novartis, Ipsen, Pfizer (C/A, RF, H); Nicholas Reed: Novartis, Ipsen, AAA Pharmaceutical Inc., Eisai (C/A, H), Novartis, Ipsen, Eisai (RF); Annemiek Walenkamp: Novartis (C/A, RF, H, SAB); Oliver Kong: Novartis (E, OI); Herve Salomon: Novartis (E); Ranjana Tavorath: Novartis (E); James C. Yao: Novartis (C/A, RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

REFERENCES

1. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–523.
2. Bendell JC, Kurkjian C, Infante JR et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. *Invest New Drugs* 2015;33:463–471.
3. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. *J Clin Oncol* 2010;28:69–76.
4. Fazio N, Buzzoni R, Baudin E et al. A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. *Anticancer Res* 2016;36:713–719.
5. Fazio N. Neuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic. *World J Clin Oncol* 2015;6:194–197.
6. Tijeras-Raballand A, Neuzillet C, Couvelard A et al. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): Molecular basis, preclinical data, and counteracting strategies. *Target Oncol* 2012;7:173–181.
7. Fonseca PJ, Uriol E, Galván JA et al. Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. *Case Rep Oncol* 2013;6:441–449.
8. Wolin EM. PI3K/AKT/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. *Cancer Lett* 2013;335:1–8.
9. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. *J Clin Oncol* 2008;26:1603–1610.
10. Meric-Bernstam F, Akcakanat A, Chen H et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. *Clin Cancer Res* 2012;18:1777–1789.
11. Blackwell K, Burris H, Gomez P et al. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. *Breast Cancer Res Treat* 2015;154:287–297.
12. Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. *Ann Oncol* 2012;23:2399–2408.
13. Papadopoulos KP, Tabernero J, Markman B et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. *Clin Cancer Res* 2014;20:2445–2456.
14. Powles T, Lackner MR, Oudard S et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2016;34:1660–1668.
15. Wise-Draper TM, Moorthy G, Salkeni MA et al. A Phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. *Target Oncol* 2017;12:323–332.
16. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Mol Cancer Ther* 2008;7:1851–1863.
17. Thomas HE, Mercer CA, Carnevalli LS et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. *Sci Transl Med* 2012;4:139ra84.
18. Xu CX, Li Y, Yue P et al. The combination of RAD001 and NVP-BEZ235 exerts synergistic anti-cancer activity against non-small cell lung cancer in vitro and in vivo. *PLoS One* 2011;6:e20899.
19. Maira SM, Pecchi S, Huang A et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. *Mol Cancer Ther* 2012;11:317–328.
20. Vandamme T, Beyens M, de Beeck KO et al. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. *Br J Cancer* 2016;114:650–658.
21. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway—beyond rapalogs. *Oncotarget* 2010;1:530–543.
22. Burris H, Rodon J, Sharma S et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. *J Clin Oncol* 2010;28(suppl 15): 3005a.
23. Gil-Martin M, Fumoleau P, Isambert N et al. A dose-finding phase Ib study of BEZ235 in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. Presented at: 38th Annual San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio: P2-16-22a.
24. Peyton JD, Rodon Ahnert J, Burris H et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. *J Clin Oncol* 2011;29(suppl 15):3066a.